Effect of Tenofovir/Emtricitabine on Hepatitis B in HIV Patients
Author Information
Author(s): Christian A. Engell, Pham Vinh Philip, Holzman Robert S., Aberg Judith A.
Primary Institution: New York University School of Medicine at Bellevue Hospital Center
Hypothesis
Does combination antiviral therapy with tenofovir and emtricitabine improve virologic outcomes in HIV/HBV-coinfected patients compared to those with prior lamivudine treatment?
Conclusion
Initial treatment with tenofovir and emtricitabine leads to a significantly shorter time to HBV DNA suppression in treatment-naïve patients compared to those with prior lamivudine treatment.
Supporting Evidence
- Treatment-naïve patients had a median time to HBV DNA suppression of 466 days.
- After 24 months, 100% of treatment-naïve patients had undetectable HBV DNA levels.
- Only 31% of treatment-experienced patients achieved undetectable HBV DNA after 24 months.
Takeaway
This study shows that starting treatment with two medicines is better for people with both HIV and hepatitis B than starting with just one medicine first.
Methodology
Retrospective review of medical records of HIV/HBV-coinfected patients, comparing treatment-naïve and treatment-experienced groups.
Potential Biases
Potential confounders include differences in baseline characteristics and adherence to treatment.
Limitations
The study is retrospective, with incomplete data on previous treatment lengths and cirrhosis, and a small sample size.
Participant Demographics
31 HIV/HBV-coinfected patients, with 12 treatment-naïve and 19 treatment-experienced.
Statistical Information
P-Value
P = .001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website